Uneasy stability in oil markets amid OPEC+ moves, Middle East ceasefire
The higher-than-expected rise in OPEC+ production quotas for August, combined with a ceasefire between Israel and Iran, has provided oil markets some breathing space and introduced a bearish sentiment to prices, but rising expectations of potential additional sanctions on Russia by Washington could soon change the landscape and keep markets on edge.
But one thing is becoming increasingly clear – even if geopolitics takes an ugly turn, it may not be able to overshadow the impact on fast-growing global supplies amid relatively slower demand.
Amid heightened tensions in the Middle East recently, oil markets experienced a peak in the fear premium when Dated Brent surged past US$80 per barrel. However, in the third quarter of this year, S&P Global Commodity Insights expects Dated Brent to decline to the mid-US$60s per barrel. And by the end of the year, strong oil supply growth relative to demand is expected to push Dated Brent into the US$50s/b.
The eight members of the OPEC+ alliance implementing voluntary crude output cuts agreed July 5 to hike their production quotas by 548,000 b/d in August, accelerating their claw back of market share. The group was of the view that members were encouraged by healthy market fundamentals, which was reflected in low oil inventories. The increase is 33% more than the previously agreed monthly increases of 411,000 b/d that the voluntary cutters had agreed in their previous three meetings. And there were expectations that the group would repeat the same for August.
The alliance is bringing barrels back to market at a time of high seasonal demand, with the US entering its driving season while Middle East countries burn more oil to meet electricity needs.
But despite this, oil markets are heading towards an oversupply scenario in the second half of 2025. Commodity Insights forecasts that the market could witness a surplus of more than 1 million b/d by the end of the year if OPEC+ members fully unwind the voluntary production cuts by October.
Global commercial inventories may rise by over 600,000 b/d in August, escalating to an average of 1.7 million b/d from September to December, influenced in part by actual OPEC+ production levels. The sustained increase in OPEC+ output is likely to exert further bearish pressure on oil prices, particularly post-summer.
Saudi Arabia's crude exports notably increased by 475,000 b/d to 6.17 million b/d in June, accounting for 90% of the total month-over-month growth among eight OPEC+ nations. This growth stemmed from inventory draws and increased production, with refinery runs and crude burn in the kingdom estimated to have risen by 140,000 b/d and 75,000 b/d month over month, respectively.
Ceasefire does not mean end of conflict
A ceasefire in the Middle East does not mean the conflict is over. The fear premium in oil prices can reappear overnight, bringing back uncertainties in the oil market. Israel's military success may have raised the possibility that Iran could ease 46 years of hostilities with the US and Israel, but for now, it's too early to jump to that conclusion.
A weakened Iran could become more repressive internally and provocative externally. Much will depend on the internal and opaque political dynamics within Iran. But the impact on the oil market could be profound if trade and investment sanctions against Iran are eased or lifted.
In addition, oil markets will closely monitor Washington's recent decision to remove Syria's oil ministry, its two refineries, and maritime authority from its sanctions list, as this could pave the way for the war-torn country's return to the international oil trade.
US sanctions on Syria were officially lifted by President Donald Trump on June 30, following earlier moves by the EU and the UK to ease economic curbs on the country.
Before the onset of the civil war in 2011, Syria pumped around 380,000-400,000 b/d of crude -- enough to meet its domestic consumption and supply some barrels to the international market.
However, Syria's oil and gas fields and infrastructure have been badly damaged and neglected. Syria's crude production has plummeted to approximately 90,000 b/d from 442,000 b/d in 2004, severely limiting export potential until production recovers, according to Commodity Insights data.
The removal of sanctions could eventually increase Syrian oil supply to global markets, though significant production increases will take time. Syrian crude grades, which are predominantly medium-heavy sour varieties, could eventually compete with similar Mediterranean grades once production and export infrastructure are restored.
Threat of secondary sanctions
Adding a layer of uncertainty to the market is the latest statement from Trump who said on July 14 that he would impose 100% secondary sanctions on any country that buys Russian exports if Russia does not reach a peace agreement with Ukraine in the next 50 days.
The announcement came amid a bipartisan push in the US Senate to pass the Sanctioning Russia Act of 2025. The bill would impose a 500% duty on all goods or services imported into the US from any country that "knowingly sells, supplies, transfers, or purchases oil, uranium, petroleum products, or petrochemical products that originated in the Russian Federation," according to the bill text.
To date in 2025, India, China, and Turkey have been the largest purchasers of Russian oil, according to data from S&P Global Commodities at Sea, collectively representing 53% of Russia's total waterborne exports. India has imported an average of 1.69 million b/d of Russian crude and condensates in 2025, while China took an average of 1.09 million b/d and Turkey 377,000 b/d, CAS data showed.
Potential 100% US tariffs on China and India would have significant market ramifications and could alter Asian crude oil flows to a large extent. By now, top buyers of Russian crude must have started pondering about their Plan B in the event new US sanctions against Russia come into force.
Sambit Mohanty is Asia Energy Analyst at S&P Global Commodity Insights, leading coverage for Platts Oilgram News for the Asia-Pacific region. Sambit is based in Singapore and has more than 25 years of experience as a senior journalist and editor analysing commodities and energy trends in the region. He holds a Master's Degree in Applied Economics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /CNW/ — USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cue Biopharma, Inc. (NASDAQ: CUE), Verastem, Inc. (NASDAQ: VSTM), Allogene Therapeutics, Inc. (NASDAQ: ALLO), and Perspective Therapeutics, Inc. (NYSE-American: CATX). While regulatory red tape tightens, surging diagnoses of colorectal and other GI cancers in young people demand quicker innovation in oncology. Forecasts suggest worldwide cancer‑drug revenues could blow past US$900 billion by 2034. Within that, next‑gen therapies built on precision techniques are slated to reach US$175.2 billion, advancing at a brisk 7.35% annual clip. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) recently held a well‑attended key opinion leader (KOL) webinar where pancreatic and gastrointestinal cancer specialists dissected pelareorep's clinical history, its biomarker data package, and where the oncolytic virus could slot into evolving chemotherapy and immunotherapy regimens. 'I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event,' said Jared Kelly, CEO of Oncolytics. 'Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers.' The panel revisited survival gains in metastatic pancreatic ductal adenocarcinoma (mPDAC), reviewed translational evidence of 'cold‑to‑hot' tumor conversion, and outlined next steps for a registration-enabling study. Management said feedback from the discussion would inform both upcoming trial designs and partnering talks now underway. The event came on the heels of Oncolytics having rolled out an expanded translational‑data review that tightened the scientific case for pelareorep, an intravenously delivered oncolytic reovirus. Renewed analyses from the GOBLET gastrointestinal cancer study and the AWARE‑1 breast cancer study confirmed that the virus replicates inside tumors, switches on interferon signaling in the immune system, and draws tumor‑infiltrating lymphocytes into the tumor microenvironment. 'This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action,' said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. 'We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.' Investigators also recorded higher PD‑L1 expression and tracked newly expanded cytotoxic T‑cell clones in blood samples that matched those inside shrinking lesions—molecular fingerprints that point to stronger responses when pelareorep is combined with standard-of-care treatments and checkpoint inhibitors. 'The collection of data here show that pelareorep works how a cancer immunotherapy should work,' said Jared Kelly, CEO of Oncolytics. 'Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs.' Clinical outcomes already hint at real‑world benefit. In more than 100 first‑line mPDAC patients, pelareorep‑based regimens achieved a 21.9% two‑year overall‑survival rate versus a 9.2% historical benchmark. A separate single‑arm study that paired pelareorep with chemotherapy and a checkpoint blocker produced a 62% objective‑response rate—especially notable given that no checkpoint therapy is approved in this cancer today. In hormone‑receptor‑positive, HER2‑negative metastatic breast cancer (HR+/HER2‑ mBC), two randomized trials added more than ten months of median overall survival, while BRACELET‑1 nearly doubled median progression‑free survival to 12.1 months compared with 6.4 months for control patients. To steer these data toward value‑creating deals and late‑stage trials, the company strengthened its leadership earlier this year by appointing industry veteran Jared Kelly as CEO and naming Andrew Aromando Chief Business Officer. The duo previously helped guide Ambrx Biopharma into a US$2 billion sale to Johnson & Johnson, experience the board believes will support capital‑efficient development and strategic partnering for pelareorep. 'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications,' said Kelly. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy.' As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. 'I'm thrilled to join Oncolytics at such a pivotal moment in its evolution,' said Aromando. 'With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term.' Pelareorep currently holds FDA Fast Track designations in mPDAC (pancreatic cancer) and HR+/HER2‑ mBC (breast cancer), along with Orphan‑Drug status for pancreatic cancer in the United States and Europe. With mechanistic proof, survival data that outperform historical controls, and fresh validation from the recent KOL event, Oncolytics Biotech is aligning its clinical, regulatory, and business strategies to move pelareorep into registration‑enabling trials and position it as a backbone immunotherapy across solid tumors. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Cue Biopharma, Inc. (NASDAQ: CUE) recently reported that adding CUE‑101 to pembrolizumab produced a 50% overall response rate in patients with recurrent/metastatic HPV‑positive head and neck cancer who had a combined positive score (CPS) ≥ 1, including the same 50% response in those with low CPS 1–19. The regimen has now generated two complete responses, an 88% 12‑month overall survival rate, and a median overall survival of 32 months, handily outperforming historical pembrolizumab data. 'The culmination of maturing data further support our conviction that CUE-101, representative of our approach with the CUE-100 series, demonstrates a potential breakthrough therapeutic approach for establishing a new standard of care,' said Dan Passeri, CEO of Cue Biopharma. 'With this maturing data, we are further emboldened in our conviction that our Immuno-STAT® platform represents transformative potential for selectively modulating the patient's immune system.' Verastem, Inc. (NASDAQ: VSTM) recently published Phase 2 RAMP 201 results in the Journal of Clinical Oncology, showing avutometinib + defactinib delivered a 31% confirmed overall response rate in recurrent low‑grade serous ovarian cancer, rising to 44% in KRAS‑mutant tumors. 'The publication of the primary analysis of the RAMP 201 study in recurrent low-grade serous ovarian cancer in the Journal of Clinical Oncology reflects the meaningful clinical advancement demonstrated by the combination of avutometinib plus defactinib for patients with recurrent low-grade serous ovarian cancer,' said John Hayslip, M.D., Chief Medical Officer at Verastem Oncology. 'The findings supported the recent FDA approval of the combination in KRAS-mutated recurrent low-grade serous ovarian cancer and our ongoing global Phase 3 RAMP 301 trial of the combination in recurrent low-grade serous ovarian cancer with and without a KRAS mutation.' Median progression‑free survival reached 12.9 months overall and 31.0 months in the KRAS‑mutant subgroup, with 82% of patients experiencing some tumor shrinkage regardless of mutation status. Back in June, Allogene Therapeutics, Inc. (NASDAQ: ALLO) presented updated Phase 1 TRAVERSE data showing a single dose of ALLO‑316 achieved a 31% confirmed response rate in heavily pre‑treated renal cell carcinoma patients whose tumors expressed CD70 in ≥ 50 % of cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' Four of five responders remain in remission—including one lasting more than 12 months—while safety remained manageable with no graft‑versus‑host disease observed. Investigators say the results highlight allogeneic CAR T's potential in solid tumors and justify continued expansion of the study. Perspective Therapeutics, Inc. (NYSE-American: CATX) recently began recruiting the third dose‑escalation cohort of its Phase 1/2a trial testing [²¹²Pb]VMT‑α‑NET in unresectable or metastatic somatostatin receptor 2 (SSTR2)‑positive neuroendocrine tumors, raising the fixed dose by 20% to 6 mCi. Earlier cohorts showed anti‑tumor activity with mostly low‑grade adverse events, prompting FDA alignment to explore whether the higher dose can further enhance efficacy. 'We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial,' commented Markus Puhlmann, Chief Medical Officer of Perspective. 'We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile.' The company plans additional safety and efficacy readouts, including dosimetry analyses, at scientific meetings in 2H 2025. Source: CONTACT:USA NEWS GROUPinfo@ 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo –
Free Malaysia Today
2 hours ago
- Free Malaysia Today
Wall Street ends mixed, crude slides as trade deadline looms
The S&P 500 closed with nominal gains as underperforming tech shares dragged the Nasdaq into the red. (AP pic) NEW YORK : The Dow gained while the Nasdaq lost ground on Tuesday and crude settled lower as investors assessed a spate of mixed earnings and signs that President Donald Trump's protracted trade war is hitting corporate profit margins, even as Trump's dealmaking deadline approached. The S&P 500 closed with nominal gains as underperforming tech shares dragged the Nasdaq into the red. Gold extended its gains in opposition to the softening dollar, and US Treasury yields eased for the third-straight session. '(Investors are) looking for additional catalysts and you're seeing some cautious comments coming out of companies,' said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. 'They're hearing mixed guidance when it comes to all this uncertainty revolving around tariffs and the direction things are heading.' Second-quarter earnings season has hit full stride, with nearly one-fifth of the companies in the S&P 500 having reported. Of those, 79% have beaten analyst expectations, according to LSEG data. Analysts expect year-on-year S&P 500 earnings growth of 7%, on aggregate, a sizable improvement over the 5.8% growth predicted as of July 1, per LSEG. Still, the effects of the trade war have begun seeping into corporate results. General Motors' second-quarter core profit slid 32% as steep tariff costs took a US$1.1-billion bite from its bottom line. Prospects of a US-European Union trade deal appeared to be fading as Washington's Aug 1 deadline loomed, prompting EU members to ramp up possible 'anti-coercion' retaliatory measures. US treasury secretary Scott Bessent said on Tuesday he would meet with his Chinese counterpart to discuss delaying the Aug 12 trade talks deadline with China again, as the world's two largest economies wrestle with the flow of technology and rare earth materials. 'These are pretty classic negotiations; nothing ever happens until it has to happen,' says Chuck Carlson, CEO at Horizon Investment Services in Hammond, Indiana. 'Nothing gets done until the deadline, then either the deadline gets extended or there's some resolution that comes out of nowhere.' 'The flip side of this is Trump's going to have to follow through eventually,' Carlson added. 'Otherwise, he's going to be the boy that cried wolf, and his negotiating power is going to be sapped because people will believe he's never going to follow through.' The Dow Jones Industrial Average rose 179.12 points, or 0.40%, to 44,502.19, the S&P 500 rose 3.99 points, or 0.06%, to 6,309.59 and the Nasdaq Composite fell 81.49 points, or 0.39%, to 20,892.69. European shares ended lower, weighed down by disappointing earnings and looming anxieties over the lack of progress in US trade negotiations. MSCI's gauge of stocks across the globe rose 0.68 points, or 0.07%, to 930.31. The pan-European STOXX 600 index fell 0.41%, while Europe's broad FTSEurofirst 300 index fell 8.50 points, or 0.39% Emerging market stocks fell 3.93 points, or 0.31%, to 1,249.53. MSCI's broadest index of Asia-Pacific shares outside Japan closed lower by 0.17%, to 657.56, while Japan's Nikkei fell 44.19 points, or 0.11%, to 39,774.92. The dollar continued to edge lower amid a subdued currency market as investors awaited any sign of progress in trade talks ahead of the August 1 deadline. The dollar index, which measures the greenback against a basket of currencies including the yen and the euro, fell 0.5% to 97.36, with the euro up 0.49% at US$1.1752. Against the Japanese yen, the dollar weakened 0.56% to 146.56. Bitcoin gained 1.98% to US$119,320.90. Ethereum declined 2.41% to US$3,668.31. US Treasury yields appeared set to notch a third-straight day of declines as the market took a breather on the heels of Monday's rally. The yield on benchmark US 10-year notes fell 2.8 basis points to 4.342%, from 4.37% late on Monday. The 30-year bond yield fell 2.6 basis points to 4.9111% from 4.937% late on Monday. The 2-year note yield, which typically moves in step with interest rate expectations for the Federal Reserve, fell 1.9 basis points to 3.833%, from 3.852% late on Monday. Oil prices weakened on growing worries over softening demand as the Aug 1 tariff deadline drew closer. US crude slid 1.47% to settle at US$66.21 per barrel, while Brent settled at US$68.59 per barrel, down 0.9%. Gold prices surpassed a five-week high, extending their gains on the softening dollar and weaker US bond yields. Spot gold rose 1.07% to US$3,431.87 an ounce. US gold futures rose 1.15% to US$3,441.00 an ounce.
Free Malaysia Today
4 hours ago
- Free Malaysia Today
Australia makes second US$525mil Aukus payment amid US review
Australia sees the nuclear-powered submarines as critical to its defence in the Indo-Pacific. (EPA Images pic) SYDNEY : Australia has paid the US A$800 million (US$525 million) in the second instalment under the Aukus nuclear submarine deal, despite an ongoing formal review of the agreement by US President Donald Trump's administration. Prime minister Anthony Albanese confirmed the latest instalment today, following an initial US$500 million paid in February. In 2023, the US, Australia and Britain unveiled details of a plan to provide Australia with nuclear-powered attack submarines from the early 2030s to counter China's ambitions in the Indo-Pacific. Australia committed to spend A$368 billion over three decades in its biggest-ever defence deal. Canberra is due to pay the US US$2 billion by year-end to support the expansion of American submarine shipyards, Reuters reported in April. 'There's a schedule of payments to be made. We have an agreement with the US as well as with the UK, it is about increasing their capacity, their industrial capacity,' Albanese told national broadcaster ABC. 'As part of that as well, we have Australians on the ground, learning those skills.' Trump launched a formal review of Aukus in June to examine whether the pact met his 'American First' criteria. It will be led by Elbridge Colby, who in the past has expressed scepticism about Aukus. Australia, which sees the submarines as critical to its own defence as tensions grow over China's military build-up, has maintained it is confident the pact will proceed. 'We support Aukus,' Albanese said. 'We have an agreement to a treaty level, with our partners, signed, of course in San Diego with the US and UK.' Washington will sell several Virginia-class nuclear-powered submarines to Australia, while Britain and Australia will later build a new Aukus-class submarine.
